Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CGRP

- PMLiVE

IQWiG unimpressed with Cosentyx in two new indications

Concludes Novartis drug has no added benefit in ankylosing spondylitis or psoriatic arthritis

- PMLiVE

Amgen and UCB’s romosozumab hits goals in male osteoporosis

Firms will discuss data with regulators before planning a new male licence application

Novartis building

NICE backs Novartis’ Entresto for heart failure

But approves narrower indication than has been authorised by Scotland's SMC

- PMLiVE

First round to Amgen in PCSK9 patent battle with Sanofi

US court concludes Praluent has infringed rival cholesterol drug Repatha

Novartis and Microsoft test Kinect MS tool

The partners have a proof-of-concept for a system that could measure the condition's symptoms

Novartis building

Novartis claims FDA breakthrough status for leukaemia treatment

Designation could speed up development and access for Novartis’ PKC412

- PMLiVE

Amgen says romosozumab on track for 2016 filing

Reports ‘significant’ reduction of fractures in post-menopausal osteoporosis patients

- PMLiVE

Amgen’s roll-out of myeloma drug Kyprolis reaches UK

Company hopes to gain NICE approval later this year

EU flag

Sandoz files for approval of Neulasta biosimilar in Europe

Amgen facing increasing competition in global biosimilar market

National Institute for Health and Care Excellence NICE logo

NICE backs Repatha but rejects cholesterol rival Praluent

New draft guidance marks a U-turn on Amgen's drug but knocks back Sanofi treatment

- PMLiVE

Novartis makes trio of appointments to senior leadership team

Michael Ball, Vas Narasimhan and Andre Wyss take on new roles

Roche Basel Switzerland

Roche shares slip as profits miss expectations

But shows solid sales growth thanks to its oncology portfolio

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links